To earn CME related to this news article, click here. April 20, 2009 — A single 5-mg intravenous infusion of zoledronic acid was at least as effective and more acceptable to patients than 5 mg of oral ...

Please provide your email address to receive an email when new articles are posted on . An annual infusion of zoledronic acid was associated with less bone loss in adults with acute spinal cord injury ...

Zometa, prescribed to reduce bone loss, cuts risk of cancer in preliminary study. SAN ANTONIO — New research adds fresh hope that a drug that strengthens bones might also fight breast cancer. Women ...

A brief discussing findings from this year's San Antonio Breast Cancer Symposium showing that research suggests that the drug Zometa may provide patients with reduced bone loss and a lesser chance of ...

SAN ANTONIO (AP) - One of the most promising new approaches for fighting breast cancer took a stunning setback Thursday when a major study showed that a bone-building drug did not stop cancer from ...

Imagine going to the doctor’s office once a year for treatment of a chronic medical condition. No daily pills. No weekly therapies. Just 30 minutes or so in a clinic. It could happen. A new ...

June 4, 2009 — The FDA this month has approved zoledronic acid infusion (Reclast, Novartis Pharmaceuticals Corp) for the prevention of postmenopausal osteoporosis during a 2-year period. "It is very ...

The efficacy of zoledronic acid after hip fracture was evaluated in 2,127 patients (1,619 women and 508 men) aged 50 years and older (N Engl J Med. 2007;357:1799-1809). The Health Outcomes and Reduced ...

New research adds fresh hope that a drug that strengthens bones might also fight breast cancer. Women who were given the drug, Zometa, as part of their initial treatment had greater tumor shrinkage ...

Bone is One of the Most Common Sites for Distant Metastases Affecting up to 75 percent of Patients with Advanced Breast Cancer THOUSAND OAKS, Calif., Nov. 8, 2010 ...